德纳维制药(DVAX)

15.50+0.000.00%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
- 德纳维制药：特定情形下协议终止赛诺菲将支付1.168亿美元反向解约金
  美股速递 · 2025-12-29
  德纳维制药：特定情形下协议终止赛诺菲将支付1.168亿美元反向解约金
- 德纳维制药股价上涨38.6%至15.43美元，因法国制药公司赛诺菲拟以约22亿美元收购该公司
  美股速递 · 2025-12-24
  德纳维制药股价上涨38.6%至15.43美元，因法国制药公司赛诺菲拟以约22亿美元收购该公司
- 生物制药股Dynavax Technologies盘前大涨40%
  环球市场播报 · 2025-12-24
  生物制药股Dynavax Technologies盘前大涨40%
- 盘前｜DVAX暴涨38%，SIDU涨超14%，英特尔遇利空一度跌5%
  老虎资讯综合 · 2025-12-24
  盘前｜DVAX暴涨38%，SIDU涨超14%，英特尔遇利空一度跌5%
- 异动解读 | 赛诺菲22亿美元收购德纳维制药，后者盘前飙涨37.56%
  异动解读 · 2025-12-24
  异动解读 | 赛诺菲22亿美元收购德纳维制药，后者盘前飙涨37.56%
- 德纳维制药美股盘前飙涨近38%
  每日经济新闻 · 2025-12-24
  德纳维制药美股盘前飙涨近38%
- 盘前异动｜DVAX、SIDU暴涨，UiPath迎利好，房多多涨6%
  老虎资讯综合 · 2025-12-24
  盘前异动｜DVAX、SIDU暴涨，UiPath迎利好，房多多涨6%
- 德纳维制药股价在盘前交易中上涨37.7%至15.30美元，因法国制药公司赛诺菲拟以15.50美元每股收购该公司
  美股速递 · 2025-12-24
  德纳维制药股价在盘前交易中上涨37.7%至15.30美元，因法国制药公司赛诺菲拟以15.50美元每股收购该公司
- 赛诺菲斥资22亿美元收购德纳维制药，拓展疫苗业务版图
  老虎资讯综合 · 2025-12-24
  赛诺菲斥资22亿美元收购德纳维制药，拓展疫苗业务版图
- 赛诺菲以每股15.50美元的现金价格收购Dynavax所有流通股
  老虎资讯综合 · 2025-12-24
  赛诺菲以每股15.50美元的现金价格收购Dynavax所有流通股
- 美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联
  老虎资讯综合 · 2025-12-02
  美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联
- 德纳维制药盘中异动股价大涨5.53%
  市场透视 · 2025-11-06
  德纳维制药盘中异动股价大涨5.53%
- 德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性
  美股速递 · 2025-10-22
  德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性
- 德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分
  美股速递 · 2025-10-22
  德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分
- 德纳维制药2024财年实现净利润27.31百万美元，同比增加527.39%
  市场透视 · 2025-02-24
  德纳维制药2024财年实现净利润27.31百万美元，同比增加527.39%
- 德纳维制药盘中异动早盘股价大涨5.03%
  市场透视 · 2025-02-21
  德纳维制药盘中异动早盘股价大涨5.03%
- Dynavax Technologies 第四季度 GAAP 每股收益 $0.05 超过预期 $0.04，销售额 $72.03M 未达预期 $72.70M
  财报速递 · 2025-02-21
  Dynavax Technologies 第四季度 GAAP 每股收益 $0.05 超过预期 $0.04，销售额 $72.03M 未达预期 $72.70M
- 带状疱疹和乙肝疫苗需求前景不明朗高盛看跌德纳维制药(DVAX.US)
  智通财经 · 2025-02-12
  带状疱疹和乙肝疫苗需求前景不明朗高盛看跌德纳维制药(DVAX.US)
- 德纳维制药盘中异动股价大跌8.94%报12.02美元
  市场透视 · 2025-02-11
  德纳维制药盘中异动股价大跌8.94%报12.02美元
- 德纳维制药盘中异动股价大跌5.00%报11.60美元
  市场透视 · 2024-11-19
  德纳维制药盘中异动股价大跌5.00%报11.60美元
公司概况
公司名称
德纳维制药
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.dynavax.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Dynavax Technologies Corporation于1996年8月29日在加利福尼亚州双螺旋结构公司的名下注册成立，1999年9月更名为 Dynavax 技术公司。该公司于2000年在特拉华州重组。该公司是一家完全集成的生物制药公司，专注于通过Toll样受体（“TLR”）刺激来利用人体先天和适应性免疫反应的力量。他们的第一个商业产品HEPLISAV-B（乙型肝炎疫苗（重组型），佐剂化）于2017年11月获得美国食品和药物管理局（“FDA”）批准用于预防所有已知乙型肝炎亚型引起的感染病毒在18岁以上的成人。他们于2018年1月开始商业运送HEPLISAV-B。他们的开发工作主要集中在刺激先天性免疫反应，与其他免疫调节剂联合治疗癌症。他们的主要研究免疫肿瘤产品是SD-101，目前正在进行阶段2临床研究评估，DV281进行阶段1安全性研究。
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-11
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 02-10
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

分时
5日
日
周
月

数据加载中...

最高

15.50

今开

15.50

量比

0.00

最低

15.50

昨收

15.50

换手率

0.00%

德纳维制药(DVAX)

公司概况

热议股票